191 completed, 26 unknown, 17 recruiting, 10 terminated. 80 Phase 4, 64 Phase 3, 60 Phase 2, 30 Not applicable, 23 Phase 1.
Follow this drug Literature Review of Ophthalmic Solutions trials Research Report on Ophthalmic Solutions
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adaptive Optics OCT Evaluation of Rhopressa's Effects on the Retinal Ganglion Cells in Glaucoma Patients Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA], Timolol Maleate 0.25% Ophthalmic Solution - Open Angle Glaucoma (OAG), Glaucoma | Phase 4 | Recruiting | Brett King | 13 | 2026-10-01 | 2026-09-29 |
| Efficacy and Safety of Topical Timolol in Secondary Intention Surgical Wounds Healing Timolol 0.5% Ophthalmic Solution, Hydrogel of placebo - Mohs Micrographic Surgery, Excision Margin | Phase 2 | Not yet recruiting | University of California, Davis | 220 | 2026-10-01 | 2026-08-18 |
| A Study of CA201A Eye Drops to Prevent Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery Ophthalmic solution (matching formulation without ascorbic acid), Ascorbic acid ophthalmic solution 5% - Corneal Endothelial Cell Loss, Corneal Endothelial Damage Following the Hard Nuclear Cataract Surgery | Phase 2 | Recruiting | Caravel Oculus Pty Ltd | 200 | 2026-07-28 | 2026-08-06 |
| Evaluation of Echothiophate in Pediatric Patients With Refractory Amblyopia Echothiophate Iodide 0.125% Ophthalmic Solution - Refractory Amblyopia | Phase 2 | Not yet recruiting | University of Oklahoma | 20 | 2026-06-01 | 2026-04-28 |
| Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction Vevye(Cyclosporine 0.1% Ophthalmic Solution) - Meibomian Gland Dysfunction (MGD) | Phase 4 | Recruiting | University of Alabama at Birmingham | 48 | 2026-06-01 | 2026-06-09 |
| Rocklatan vs Latanoprost Post-DSLT Rocklatan 0.02%-0.005% Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution - Glaucoma | Phase 4 | Recruiting | Eye Centers of Southeast Texas | 36 | 2026-05-14 | 2026-05-22 |
| Vevye + Flarex Combination Therapy for Dry Eye Vevye(Cyclosporine 0.1% Ophthalmic Solution), Flarex - Dry Eye | Phase 4 | Enrolling by invitation | Canyon City Eyecare | 60 | 2026-04-03 | 2026-04-28 |
| Human Umbilical Cord Mesenchymal Stem Cell-derived Small Extracellular Vesicles for the Treatment of Dry Eye Disease Human umbilical cord mesenchymal stem cell-derived small extracellular vesicle (sEV) eye drops. - Dry Eye Disease, Umbilical Cord Mesenchymal Stem Cell-derived Small Extracellular Vesicles | Early Phase 1 | Recruiting | The First Affiliated Hospital of Xiamen University | 20 | 2026-03-31 | 2026-06-03 |
| Efficacy of 0.5% Topical Timolol Eye Drops in the Treatment of Post-Inflammatory Erythema Following Acne Vulgaris Timolol 0.5% Ophthalmic Solution, Intense Pulsed Light - Post Inflammtory Erythema, Acne Vulgaris | Early Phase 1 | Recruiting | Pham Ngoc Thach University of Medicine | 60 | 2026-03-09 | 2026-04-01 |
| Rebamipide Versus Diquafosol for Perioperative Dry Eye in Cataract Surgery Rebamipide 2% ophthalmic solution, Diquafosol 3% ophthalmic solution - Dry Eye Disease (DED), Cataract | Phase 4 | Not yet recruiting | Samsung Medical Center | 60 | 2026-03-01 | 2026-02-09 |
| An Efficacy and Safety Study of DFL24498 in the Treatment of AKC DFL24498, Vehicle, dexamethasone sodium phosphate (DSP) ophthalmic solution - Atopic Keratoconjunctivitis | Phase 3 | Recruiting | Dompé Farmaceutici S.p.A | 153 | 2025-12-01 | 2026-09-21 |
| 24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution, Latanoprost 0.005% Ophthalmic Solution - Open Angle Glaucoma, Ocular Hypertension | Phase 4 | Recruiting | Mayo Clinic | 30 | 2025-11-21 | 2026-05-01 |
| Corneal Crosslinking for Treatment of Progressive Keratoconus or Corneal Ectasia Riboflavin 0.1% ophthalmic solution and pulsed light, Riboflavin 0.1% ophthalmic solution and non-pulsed light - Keratoconus, Corneal Ectasia | Phase 2 / Phase 3 | Recruiting | Price Vision Group | 500 | 2025-10-01 | 2026-09-25 |
| Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution, Netarsudil 0.02%/latanoprost 0.005% ophthalmic solution - Ocular Hypertension, Open Angle Glaucoma | Phase 3 | Completed | Alcon Research | 489 | 2025-09-02 | 2026-04-21 |
| Efficacy of Topical Atropine Eye Drops for Control of Myopia Progression Among Children Attending Mansoura University Ophthalmic Center Atropine 0.05% Eye drops, Placebo ophthalmic solution - Myopia | Phase 2 / Phase 3 | Not yet recruiting | Mansoura University | 45 | 2025-09-01 | 2025-09-09 |
| Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG) QLS-111 ophthalmic solution (0.015%), Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol) - Normal Tension Glaucoma (NTG), Low-Tension Glaucoma, Bilateral | Phase 2 | Completed | Qlaris Bio, Inc. | 37 | 2025-08-13 | 2026-04-03 |
| Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract Surgery Bromfenac 0.09 % Ophthalmic Solution, Nepafenac 0.3% Oph Susp, diclofenac 0.1% ophthalmic susp. - Macular Oedema, Cataract Surgery | Not applicable | Recruiting | Nemocnice Kolín | 150 | 2025-08-01 | 2025-09-17 |
| The Effect of 0.01% Atropine Eye Drops on Axial Length and Refraction in Myopic Children Compared to a Control Group Atropine 0.01% eye drops - Focus on Axial Length | Phase 2 | Recruiting | Liaquat National Hospital & Medical College | 60 | 2025-07-13 | 2026-03-06 |
| Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension PA5108 Ocular Implant low dose, PA5108 Ocular Implant, high dose, Latanoprost 0.005% Ophthalmic Solution - Glaucoma, Open-Angle, Ocular Hypertension | Phase 2 | Active not recruiting | PolyActiva Pty Ltd | 75 | 2025-05-31 | 2026-07-08 |
| Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost Simbrinza 0.2%-1% Ophthalmic Suspension, Rocklatan 0.02%-0.005% Ophthalmic Solution, Cosopt PF 2%-0.5% Ophthalmic Solution - Open Angle Glaucoma | Phase 4 | Recruiting | Prairie Eye Center | 70 | 2025-05-14 | 2025-05-15 |
Showing 20 of 266. Sign in to see all of them.
Ocular Hypertension (57) · Glaucoma (53) · Glaucoma, Open-Angle (48) · Dry Eye Syndromes (47) · Cataract (16) · Myopia (16) · Conjunctivitis, Allergic (11) · Hypertension (6) · Conjunctivitis, Bacterial (5) · Fuchs' Endothelial Dystrophy (5) · Keratoconus (5) · Macular Edema (5) · Conjunctivitis (4) · Low Tension Glaucoma (4) · Myopia, Degenerative (4)
Alcon Research (45) · Allergan (25) · Aerie Pharmaceuticals (4) · Merck Sharp & Dohme LLC (4) · Eyenovia Inc. (3) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (3) · AbbVie (2) · Alexandria University (2) · Bausch & Lomb Incorporated (2) · Corxel Pharmaceuticals (2) · Dompé Farmaceutici S.p.A (2) · Harbour BioMed (Guangzhou) Co. Ltd. (2) · Laboratorios Sophia S.A de C.V. (2) · Novaliq GmbH (2) · Qlaris Bio, Inc. (2)
United States (108) · Egypt (13) · Italy (13) · China (10) · South Korea (10) · Spain (8) · Canada (6) · France (6) · Germany (6) · Belgium (5) · India (5) · United Kingdom (5) · Israel (4) · Austria (3) · Czechia (3)
Abd-Elazeem A Elbakry, MD (2) · Amy Schaberg, BSN (2) · Jason Hsu, MD (2) · Jianfeng Zhu (2) · Pamela Smith, B.S. (2) · Severine Durier, Pharm.D (2) · Sonja Kroesser, PhD (2) · Steve Burmaster, PhD (2) · Theresa Landry, PhD (2)
PMID 21750611, PMID 10815152, PMID 14609821, PMID 15232472, PMID 15502479, PMID 15691272, PMID 16633024, PMID 17493572, PMID 18402717, PMID 18538406, PMID 19365194, PMID 19387867, PMID 19668532, PMID 20465801, PMID 20538982, PMID 20553122, PMID 21878847, PMID 22458918, PMID 23406601, PMID 23681371, PMID 24339307, PMID 25138758, PMID 25163405, PMID 25244402, PMID 25260889, PMID 25430900, PMID 25432143, PMID 25931807, PMID 26192781, PMID 2788589, PMID 28709412, PMID 29148532, PMID 31134171, PMID 31482510, PMID 32376427, PMID 32440977, PMID 32557558, PMID 33595256, PMID 34481407, PMID 34707360, PMID 34798680, PMID 34985175, PMID 34996516, PMID 35192105, PMID 35622535, PMID 35909461, PMID 36175821, PMID 36996503, PMID 37022717, PMID 37043339
2005 (1), 2008 (1), 2009 (1), 2019 (1), 2023 (1), 2025 (1), R01EY022124 (1), R01EY031315 (1), R44EY014772 (1)